MRKR News and Press, Marker Therapeutics Inc. From 06/16/21

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference PR Newswire HOUSTON , June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the developmen...

Penny Stocks To Buy According To Top Wall Street Firms What do you look for when it comes to finding penny stocks to buy? Are you hunting for momentum? Should corporate filings be part of your research? Will news headlines play a role in your decision-making? What about industry sentime...

3 Penny Stocks to Watch Right Now While 2021 still has over six months left, penny stocks remain at top of mind. And to find the best penny stocks to buy , investors often need to think outside of the box. It’s worth noting that both penny stocks and blue chips have trade...

Palm Beach, FL –May 20, 2021 – Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to trea...

Marker Therapeutics, Inc. (MRKR) Q1 2021 Earnings Conference Call May 12, 2021, 05:00 PM ET Company Participants Peter Hoang - President and CEO Anthony Kim - CFO Mythili Koneru - Chief Medical Officer Juan Vera - Chief Development Officer Conference Call Participants Joseph Catanzaro - Piper...

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Company to host conference call and webcast today at 5:...

Gainers: [[LAUR]] +14.2%. [[TEAM]] +7.5%. [[FIVN]] +7.3%. [[TXRH]] +6.1%. [[XERS]] +5.7%.Losers: [[ARDX]] -16.8%. [[MVIS]] -16.8%. [[SWKS]] -7.3%. [[MRKR]] -5.6%. [[LLNW]] -4.9%. For further details see: SWKS, TEAM, MVIS and FIVN among after-hours movers

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 PR Newswire HOUSTON , April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-o...

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Ma...

Today, we take an in-depth look at clinical-stage immuno-oncology company named Marker Therapeutics. The company has multiple 'shots on goal', heavy insider buying and recently addressed its funding needs. A full investment analysis follows in the paragraphs below. For furth...